{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T20:38:24Z","timestamp":1794861504621,"version":"4.9.1"},"reference-count":22,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Background: Inflammatory activity in rheumatoid arthritis can be determined by normal blood count ratios such as Neutrophil Lymphocyte Ratio (NLR), Platelet Lymphocyte Ratio (PLR), Systemic Immune Inflammation Index (SII), and C-reactive Protein (CRP). Objective: The aim of this research is to determine how these markers change after therapy and whether their pre- and post-treatment differences follow patterns that allow for simple parametric analyses. Methods: A prospective cohort of 52 RA patients (30 females and 22 males) was examined. The patients\u2019 blood samples were tested at baseline and at the end of their 6-month Infliximab treatment. Hematologic markers such as NLR, PLR, and SII were calculated from the complete blood count (CBC), and CRP levels were measured. The statistical methods of Shapiro\u2013Wilk (SW), Kolmogorov\u2013Smirnov (KS), and Anderson\u2013Darling (AD) were used, and later, paired t-tests were used to generate statistics where necessary. Results: Post-treatment measurements were consistently lower for all four biomarkers. QQ-plots and formal tests revealed that the differences between findings were essentially normal, allowing for paired t-tests. The mean decreases were as follows: NLR \u22121.10 (95% CI \u22121.48 to \u22120.71), PLR \u221243.0 (\u221255.4 to \u221230.7), SII \u2212299 (\u2212388 to \u2212211), and CRP \u221211.36 (\u221213.18 to \u22129.54), all p &lt; 0.001. CRP showed the greatest drop, with significant decreases in PLR and SII and a moderate decline in NLR, indicating therapy-related attenuation of systemic inflammation. Conclusions: The study shows that six months of infliximab therapy results in a consistent post-treatment decrease in all four biomarkers: NLR, PLR, SII, and CRP. Because the pre-post differences were roughly normal, CRP revealed the greatest decrease, with significant decreases in PLR and SII and a moderate decrease in NLR, consistent with systemic inflammation reduction. When combined, the CBC-derived indices track with CRP and can serve as practical, low-cost markers for monitoring therapy response in RA, despite the single-arm design.<\/jats:p>","DOI":"10.3390\/biomedicines14010255","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T13:55:34Z","timestamp":1769176534000},"page":"255","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Role of NLR, PLR, SII and CRP Pre- and Post-Treatment with Infliximab in Rheumatoid Arthritis"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4243-5339","authenticated-orcid":false,"given":"Diellor","family":"Rizaj","sequence":"first","affiliation":[{"name":"Rheumatology Clinic, University Clinical Center of Kosovo, 10000 Prishtina, Kosovo"},{"name":"Faculty of Medical Sciences, UBT College Higher Education Institution, 10000 Prishtina, Kosovo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6101-817X","authenticated-orcid":false,"given":"Avni","family":"Kryeziu","sequence":"additional","affiliation":[{"name":"Rheumatology Clinic, University Clinical Center of Kosovo, 10000 Prishtina, Kosovo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artidon","family":"Kelmendi","sequence":"additional","affiliation":[{"name":"Rheumatology Clinic, University Clinical Center of Kosovo, 10000 Prishtina, Kosovo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7284-4762","authenticated-orcid":false,"given":"Behar","family":"Raci","sequence":"additional","affiliation":[{"name":"Clinic of Oncology, University Clinical Center of Kosovo, 10000 Prishtina, Kosovo"},{"name":"Faculty of Medicine, University of Prishtina, 10000 Prishtina, Kosovo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0744-910X","authenticated-orcid":false,"given":"Shend","family":"Kryeziu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Prishtina, 10000 Prishtina, Kosovo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Visar","family":"Baftijari","sequence":"additional","affiliation":[{"name":"Clinic of Internal Medicine, University Clinical Center of Kosovo, 10000 Prishtina, Kosovo"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s00296-020-04731-0","article-title":"The global prevalence of rheumatoid arthritis: A meta-analysis based on a systematic review","volume":"41","author":"Almutairi","year":"2021","journal-title":"Rheumatol. Int."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.immuni.2017.02.006","article-title":"Immunopathogenesis of Rheumatoid Arthritis","volume":"46","author":"Firestein","year":"2017","journal-title":"Immunity"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.semarthrit.2014.05.001","article-title":"The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: A systematic review and meta-analysis","volume":"44","author":"Matcham","year":"2014","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1185\/03007990903422307","article-title":"Societal cost of rheumatoid arthritis patients in the US","volume":"26","author":"Birnbaum","year":"2010","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e670","DOI":"10.1016\/S2665-9913(23)00232-1","article-title":"Global, regional, and national burden of other musculoskeletal disorders, 1990\u20132020, and projections to 2050: A systematic analysis of the Global Burden of Disease Study 2021","volume":"5","author":"Gill","year":"2023","journal-title":"Lancet Rheumatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The Pathogenesis of Rheumatoid Arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(94)90628-9","article-title":"Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor \u03b1 (cA2) versus placebo in rheumatoid arthritis","volume":"344","author":"Elliott","year":"1994","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"vi5","DOI":"10.1093\/rheumatology\/kes279","article-title":"ACR\/EULAR 2010 rheumatoid arthritis classification criteria","volume":"51","author":"Kay","year":"2012","journal-title":"Rheumatology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/1756-185X.12582","article-title":"Two new inflammatory markers associated with Disease Activity Score-28 in patients with rheumatoid arthritis: Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio","volume":"18","author":"Uslu","year":"2015","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/apm.12722","article-title":"Comparisons of neutrophil-, monocyte-, eosinophil-, and basophil- lymphocyte ratios among various systemic autoimmune rheumatic diseases","volume":"125","author":"Yang","year":"2017","journal-title":"APMIS"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3343\/alm.2019.39.4.345","article-title":"The Platelet-to-Lymphocyte Ratio as an Inflammatory Marker in Rheumatic Diseases","volume":"39","author":"Gasparyan","year":"2019","journal-title":"Ann. Lab. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2478\/fco-2024-0009","article-title":"The importance of neutrophil-to-lymphocyte ratio before and after radiation in breast cancer patients","volume":"15","author":"Raci","year":"2024","journal-title":"Forum Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/CIRCRESAHA.115.306656","article-title":"From C-Reactive Protein to Interleukin-6 to Interleukin-1","volume":"118","author":"Ridker","year":"2016","journal-title":"Circ. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.intimp.2016.04.006","article-title":"Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) were associated with disease activity in patients with systemic lupus erythematosus","volume":"36","author":"Wu","year":"2016","journal-title":"Int. Immunopharmacol."},{"key":"ref_15","unstructured":"(2025, October 03). Ahmed BenSaida Shapiro-Wilk and Shapiro-Francia Normality Tests. Available online: https:\/\/www.mathworks.com\/matlabcentral\/fileexchange\/13964-shapiro-wilk-and-shapiro-francia-normality-tests."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1136\/ard.2009.126532","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1136\/ard.2010.147751","article-title":"Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: Subanalysis of the BeSt study","volume":"70","author":"Klarenbeek","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"586","DOI":"10.4149\/BLL_2019_096","article-title":"Neutrophil-lymphocyte and platelet-lymphocyte rate and their seasonal differences in ankylosing spondylitis and rheumatoid arthritis patients using anti-TNF medication","volume":"120","author":"Enginar","year":"2019","journal-title":"Bratisl. Med. J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"248","DOI":"10.7861\/clinmedicine.10-3-248","article-title":"Rheumatoid arthritis: Assessing disease activity and outcome","volume":"10","author":"Symmons","year":"2024","journal-title":"Clin. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"6261","DOI":"10.3748\/wjg.v23.i34.6261","article-title":"Systemic immune-inflammation index for predicting prognosis of colorectal cancer","volume":"23","author":"Chen","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2147\/JIR.S283835","article-title":"The Associations of Two Novel Inflammation Indexes, SII and SIRI with the Risks for Cardiovascular Diseases and All-Cause Mortality: A Ten-Year Follow-Up Study in 85,154 Individuals","volume":"14","author":"Jin","year":"2021","journal-title":"J. Inflamm. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11255-022-03320-3","article-title":"Could systemic immune inflammation index be a new parameter for diagnosis and disease activity assessment in systemic lupus erythematosus?","volume":"55","author":"Ozdemir","year":"2023","journal-title":"Int. Urol. Nephrol."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/14\/1\/255\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T10:41:54Z","timestamp":1769510514000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/14\/1\/255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["biomedicines14010255"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines14010255","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]}}}